Vistagen Therapeutics Share Price (NASDAQ: VTGN)

$3.33

▲

0.1

(3.1%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Vistagen Therapeutics Stock chart to analyse performance

Vistagen Therapeutics stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$3.20
Today's High:$3.35
$3.33
3.9%
Downside
Day's Volatility :4.48%
Upside
0.6%
52 Weeks Low:$1.90
52 Weeks High:$3.58
$3.33
42.94%
Downside
52 Weeks Volatility :46.93%
Upside
6.98%

Vistagen Therapeutics Stock Returns

Period	Vistagen Therapeutics Inc	Index (Russel 2000)
3 Months	38.14%	0.0%
6 Months	34.54%	0.0%
1 Year	-0.3%	0.0%
3 Years	-34.35%	-4.7%

Vistagen Therapeutics Inc Key Stats

Check Vistagen Therapeutics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$3.23
Open	$3.195
Today's High	$3.35
Today's Low	$3.2
Market Capitalization	$99.1M
Today's Volume	$586.6K
52 Week High	$3.58
52 Week Low	$1.9
Revenue TTM	$646.0K
EBITDA	$-59.5M
Earnings Per Share (EPS)	$-1.79
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-69.05%

Stock Returns calculator for Vistagen Therapeutics Stock including INR - Dollar returns

The Vistagen Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Vistagen Therapeutics investment value today

Current value as on today

₹1,04,391

Returns

₹4,391

(+4.39%)

Returns from Vistagen Therapeutics Stock

₹893 (-0.89%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Vistagen Therapeutics Stock

-67%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Vistagen Therapeutics Stock from India on INDmoney has decreased by -67% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Vistagen Therapeutics Inc

Name
Holdings %
Name
Holdings %
TCG Crossover Management, LLC
8.96%
StemPoint Capital LP
8.08%
Nantahala Capital Management, LLC
6.63%
Vanguard Group Inc
5.89%
COMMODORE CAPITAL LP
5.27%
JPMorgan Chase & Co
2.51%

Analyst Recommendation on Vistagen Therapeutics Stock

Rating

Trend

Buy

90%Buy

10%Hold

0%Sell

Based on 10 Wall street analysts offering stock ratings for Vistagen Therapeutics(by analysts ranked 0 to 5 stars)

Vistagen Therapeutics Share Price Target

What analysts predicted

Upside of 290.39%

Target:

$13.00

Current:

$3.33

Vistagen Therapeutics share price target is $13.00, a slight Upside of 290.39% compared to current price of $3.33 as per analysts' prediction.

Vistagen Therapeutics Stock Insights

Price Movement
In the last 7 days, VTGN stock has moved up by 5.7%
Increasing Revenue
Revenue is up for the last 2 quarters, -15.0K → 244.0K (in $), with an average increase of 106.2% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -13.63M → -15.09M (in $), with an average decrease of 10.7% per quarter
VTGN vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 73.9%
VTGN vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.6% return, outperforming this stock by 148.7%
Price to Sales
ForVTGN every $1 of sales, investors are willing to pay $159.5, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.5 for every $1 of sales.

Vistagen Therapeutics Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY20

FY21

FY22

FY23

FY24

FY25

	FY20	Y/Y Change
Revenue	$334.0K	-
Net Income	$-20.8M	↓ 15.52%
Net Profit Margin	-6.2K%	-

	FY21	Y/Y Change
Revenue	$1.1M	↑ 226.2%
Net Income	$-17.9M	↓ 13.67%
Net Profit Margin	-1.6K%	↑ 4573.67%

	FY22	Y/Y Change
Revenue	$1.1M	↑ 1.78%
Net Income	$-47.8M	↑ 166.32%
Net Profit Margin	-4.3K%	↓ 2661.1%

	FY23	Y/Y Change
Revenue	$-227.3K	↓ 120.5%
Net Income	$-59.2M	↑ 24.05%
Net Profit Margin	26.1K%	↑ 30373.05%

	FY24	Y/Y Change
Revenue	$1.1M	↓ 568.1%
Net Income	$-29.4M	↓ 50.44%
Net Profit Margin	-2.8K%	↓ 28825.45%

	FY25	Y/Y Change
Revenue	$486.0K	↓ 54.32%
Net Income	$-51.4M	↑ 75.12%
Net Profit Margin	-10.6K%	↓ 7820.25%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$197.3K	↓ 52.04%
Net Income	$-9.5M	↑ 49.95%
Net Profit Margin	-4.8K%	↓ 3282.39%

	Q2 FY24	Q/Q Change
Revenue	$84.0K	↓ 57.43%
Net Income	$-10.7M	↑ 12.73%
Net Profit Margin	-12.8K%	↓ 7951.53%

	Q3 FY24	Q/Q Change
Revenue	$183.0K	↑ 117.86%
Net Income	$-13.0M	↑ 20.76%
Net Profit Margin	-7.1K%	↑ 5694.87%

	Q4 FY24	Q/Q Change
Revenue	$234.0K	↑ 27.87%
Net Income	$-14.1M	↑ 8.7%
Net Profit Margin	-6.0K%	↑ 1061.57%

	Q1 FY25	Q/Q Change
Revenue	$-15.0K	↓ 106.41%
Net Income	$-13.6M	↓ 3.22%
Net Profit Margin	90.9K%	↑ 96920.94%

	Q2 FY25	Q/Q Change
Revenue	$244.0K	↓ 1726.67%
Net Income	$-15.1M	↑ 10.71%
Net Profit Margin	-6.2K%	↓ 97086.48%

FY20

FY21

FY22

FY23

FY24

FY25

	FY20	Y/Y Change
Profit	$-103.1K	↑ 13.05%

	FY21	Y/Y Change
Profit	$1.1M	↓ 1156.74%

	FY22	Y/Y Change
Profit	$1.1M	↑ 1.78%

	FY23	Y/Y Change
Profit	$-227.3K	↓ 120.5%

	FY24	Y/Y Change
Profit	$1.1M	↓ 568.1%

	FY25	Y/Y Change
Profit	$486.0K	↓ 54.32%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$197.3K	↓ 52.04%

	Q2 FY24	Q/Q Change
Profit	$84.0K	↓ 57.43%

	Q3 FY24	Q/Q Change
Profit	$183.0K	↑ 117.86%

	Q4 FY24	Q/Q Change
Profit	$234.0K	↑ 27.87%

	Q1 FY25	Q/Q Change
Profit	$-15.0K	↓ 106.41%

	Q2 FY25	Q/Q Change
Profit	$75.0K	↓ 600.0%

FY20

FY21

FY22

FY23

FY24

FY25

	FY20	Y/Y Change
Operating Cash Flow	$-15.8M	↑ 8.46%
Investing Cash Flow	$-275.4K	↑ 58.28%
Financing Cash Flow	$4.0M	↓ 76.97%

	FY21	Y/Y Change
Operating Cash Flow	$-12.1M	↓ 23.38%
Investing Cash Flow	$-275.4K	↑ 0.0%
Financing Cash Flow	$114.1M	↑ 2744.16%

	FY22	Y/Y Change
Operating Cash Flow	$-45.3M	↑ 274.84%
Investing Cash Flow	$-200.4K	↓ 27.23%
Financing Cash Flow	$10.5M	↓ 90.81%

	FY23	Y/Y Change
Operating Cash Flow	$-49.7M	↑ 9.85%
Investing Cash Flow	$-740.3K	↑ 269.41%
Financing Cash Flow	$-1.0M	↓ 109.94%

	FY24	Y/Y Change
Operating Cash Flow	$-25.8M	↓ 48.08%
Investing Cash Flow	$-61.0K	↓ 91.76%
Financing Cash Flow	$128.4M	↓ 12419.1%

	FY25	Y/Y Change
Operating Cash Flow	$-42.1M	↑ 63.08%
Investing Cash Flow	$-13.1M	↑ 21454.1%
Financing Cash Flow	$3.2M	↓ 97.5%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-7.2M	↑ 58.69%
Investing Cash Flow	$-28.7K	↓ 11.15%
Financing Cash Flow	$-167.8K	↓ 100.18%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-10.9M	↑ 51.02%
Investing Cash Flow	$-5.5M	↑ 18948.78%
Financing Cash Flow	$88.0K	↓ 152.44%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-10.9M	↑ 0.16%
Investing Cash Flow	$-7.8M	↑ 42.42%
Financing Cash Flow	$0.0	↓ 100.0%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-10.3M	↓ 5.57%
Investing Cash Flow	$-422.0K	↓ 94.58%
Financing Cash Flow	$1.2M	-

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-10.1M	↓ 2.12%
Investing Cash Flow	$527.0K	↓ 224.88%
Financing Cash Flow	$2.0M	↑ 66.61%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-18.8M	↑ 87.3%
Investing Cash Flow	$-788.0K	↓ 249.53%
Financing Cash Flow	$1.5M	↓ 23.73%

Vistagen Therapeutics Technicals Summary

Sell

Neutral

Buy

Vistagen Therapeutics is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Vistagen Therapeutics Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Vistagen Therapeutics Inc	14.73%	34.54%	-0.3%	-34.35%	-83.46%
Regeneron Pharmaceuticals, Inc.	6.48%	-15.2%	-50.31%	-3.3%	-2.01%
Beone Medicines Ltd	1.77%	24.81%	62.78%	79.11%	29.69%
Vertex Pharmaceuticals Incorporated	-14.45%	-19.13%	-17.84%	34.68%	41.87%
Alnylam Pharmaceuticals, Inc.	13.79%	83.28%	75.87%	111.28%	242.25%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Vistagen Therapeutics Inc	NA	NA	0.0	-1.73	-0.69	-0.41	NA	1.94
Regeneron Pharmaceuticals, Inc.	14.6	14.6	1.2	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.86	27.86	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Vistagen Therapeutics Inc	Buy	$99.1M	-83.46%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$61.4B	-2.01%	14.6	31.37%
Beone Medicines Ltd	NA	$36.5B	29.69%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.5B	41.87%	27.86	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.5B	242.25%	NA	-12.96%

About Vistagen Therapeutics Inc

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase II clinical trial to treat major depressive disorder. It also develops PH80, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase II clinical trial for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women's health disorders; PH15, an investigational pherine nasal spray, which is in Phase II clinical trial for the treatment to improve cognitive impairment caused by mental fatigue and potentially other disorders; PH284, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase II clinical trial to treat loss of appetite associated with chronic disorders, such as cancer or heart disease, as well as cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain for treating depression and neurological disorders. In addition, the company's clinical-stage pipeline consists of intranasal product candidates comprising pherines. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

Organization	Vistagen Therapeutics
Employees	57
CEO	Mr. Shawn K. Singh J.D.
Industry	Health Technology

Key Management of Vistagen Therapeutics Inc

Name	Title
Mr. Shawn K. Singh J.D.	President, CEO & Director
Ms. Cynthia Lynn Anderson CPA	VP & Chief Financial Officer
Mr. Joshua S. Prince M.B.A.	Chief Operating Officer
Mr. Reid G. Adler Esq., J.D.	Chief Legal Officer
Mr. Mark Adrian McPartland	Senior Vice President of Investor Relations
Ms. Michelle Peters Wellington	Vice President of Communications
Ms. Elissa Cote	Chief Corporate Development Officer
Ms. Trisha Fitzmaurice	Senior Vice President of Human Resources
Dr. Allen Easley Cato III, M.D., Ph.D.	Senior Vice President of Development Operations
Dr. Mark J. Ginski Ph.D.	Senior VP and Head of Chemistry, Manufacturing & Controls

Important FAQs about investing in VTGN Stock from India :

What is Vistagen Therapeutics share price today?

Vistagen Therapeutics share price today is $3.33 as on August 30, 2025 at 1:29 am IST at the close of the market. Vistagen Therapeutics share today touched a day high of $3.35 and a low of $3.20.

What is the 52 week high and 52 week low for Vistagen Therapeutics share?

Vistagen Therapeutics share touched a 52 week high of $3.58 and a 52 week low of $1.90. Vistagen Therapeutics stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $3.33, lower by 6.98% versus the 52 week high.

How to invest in Vistagen Therapeutics Stock (VTGN) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Vistagen Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Vistagen Therapeutics Shares that will get you 0.4505 shares as per Vistagen Therapeutics share price of $3.33 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Vistagen Therapeutics Stock (VTGN) from India?

Indian investors can start investing in Vistagen Therapeutics (VTGN) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Vistagen Therapeutics stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Vistagen Therapeutics share’s latest price of $3.33 as on August 30, 2025 at 1:29 am IST, you will get 3.0030 shares of Vistagen Therapeutics. Learn more about fractional shares .

What are the returns that Vistagen Therapeutics has given to Indian investors in the last 5 years?

Vistagen Therapeutics stock has given -83.46% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?